Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records reported in 1995

12 records with a recorded report or completion year of 1995.

Showing 0 records on this page

Records

12 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
GHRP6-PH1-GHGHRP-6Phase 1ReportedPhase 1 ascending dose1995Low
GHRP6-PH1-GH-ADHERENCEprogramme recordGHRP-6Phase 1ReportedObservational1995Very low
GHRP6-PH1-GH-BIOMARKERprogramme recordGHRP-6Phase 1ReportedRandomised, double-blind, placebo-controlled1995Very low
GHRP6-PH1-GH-ELDERLYprogramme recordGHRP-6Phase 1ReportedRandomised, double-blind, placebo-controlled1995Very low
GHRP6-PH1-GH-OLEprogramme recordGHRP-6Phase 1ReportedSingle-arm open-label1995Very low
GHRP6-PH1-GH-QOLprogramme recordGHRP-6Phase 1ReportedRandomised, double-blind, placebo-controlled1995Very low
HEX-PH1-GHHexarelinPhase 1ReportedPhase 1 ascending dose1995Low
HEX-PH1-GH-DDIprogramme recordHexarelinPhase 1ReportedRandomised crossover1995Very low
HEX-PH1-GH-HEPATIC-IMPprogramme recordHexarelinPhase 1ReportedPhase 1 ascending dose1995Very low
HEX-PH1-GH-OLEprogramme recordHexarelinPhase 1ReportedSingle-arm open-label1995Very low
HEX-PH1-GH-PKprogramme recordHexarelinPhase 1ReportedPhase 1 ascending dose1995Very low
HEX-PH1-GH-RENAL-IMPprogramme recordHexarelinPhase 1ReportedPhase 1 ascending dose1995Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.